Northrop Grumman stock has recovered to pre-Covid levels, while competitor Boeing's stock remains 30% below its pre-Covid peak. Both companies have a sizable order backlog that can sustain revenues for more than two years. At the same time, multi-year government contracts safeguard long-term...
Northrop Grumman stock has recovered to pre-Covid levels, while competitor Boeing's stock remains 30% below its pre-Covid peak. Both companies have a sizable order backlog that can sustain revenues for more than two years. At the same time, multi-year government contracts safeguard long-term...
Share this Article
Recommended